Table 1 Management of hypertrophic scars and keloids: systematic review
Reference | Sample size | Study | Randomization | Controlled | Comparative | LOE | Patients age | Number of scars | Treatment |
|---|---|---|---|---|---|---|---|---|---|
Aggarwal H et al., 2008 [60] | 50 patients | Prospective | No | No | No | IV | N.A. | 50 | Bleomycin |
Ahuja RB and Chatterjee P, 2013 [61] | 40 patients | Prospective | Yes | No | Yes | II | Average age: N.A. (range: 15–60) | 22 | Triamcinolone |
26 | Verapamil | ||||||||
Espana A et al., 2001 [58] | 13 patients | Prospective | No | No | No | IV | Average age: 24 years (range: 14–36) | 13 | Bleomycin |
Griffith BH, 1966 [59] | 29 patients | Retrospective | No | No | No | IV | Average age: 22 years (range: 1–58) | 37 | Triamcinolone |
Gupta S and Kumar B, 2001 [62] | 12 patients | Prospective | No | No | No | IV | Average age: 31 years (range: 19–50) | 12 | Cryosurgery |
Kang N et al., 2006 [63] | 5 patients | Prospective | No | No | No | IV | Average age: 31 years (range: 12–46) | N.A. | Collagenase |
Kiil J, 1977 [64] | 44 patients | Prospective | No | No | No | IV | Average age: 16 years (range: 6–46) | N.A. | Triamcinolone |
Kontochristopoulos et al., 2005 [65] | 20 patients | Prospective | No | No | No | IV | Average age: 30 years (range: 12–65) | N.A. | 5-Fluorouracil |
Manuskiatti W and Fitzpatrick RE, 2002 [66] | 10 patients | Prospective | Yes | No | Yes | II | Average age: N.A. (range: 25–74) | 10 | 5-Fluorouracil |
Triamcinolone | |||||||||
Margareth Shanthi FX et al., 2008 [67] | 54 patients | Prospective | Yes | No | Yes | II | Average age: 20 years (range: 10–50) | N.A. | Triamcinolone |
Average age: 26 years (range: 10–50) | N.A. | Verapamil | |||||||
Saray Y and Güleç AT, 2005 [68] | 14 patients | Prospective | No | No | No | IV | Average age: 32 years (range: 16–73) | 15 | Bleomycin |